news
Hims & Hers plans big peptide push, BPC-157 included
Telehealth giant Hims & Hers announced plans to rapidly expand into six experimental peptide therapies, including BPC-157 and TB-500. This move signals a significant push into advanced longevity and recovery treatments, aiming to capture a growing market for compounds beyond traditional medications. It's a clear signal for where direct-to-consumer health is heading next.
Telehealth giant Hims & Hers announced plans to rapidly expand into six experimental peptide therapies, including BPC-157 and TB-500. This move signals a significant push into advanced longevity and recovery treatments, aiming to capture a growing market for compounds beyond traditional medications. It's a clear signal for where direct-to-consumer health is heading next.
The architecture take
I’ve been watching Hims & Hers, and this move into peptides like BPC-157 and TB-500 tells me they’re skipping the basic stuff straight to compounds consumers are already hunting for. BPC-157, for example, is usually linked to gut repair and tendon healing. TB-500 is about cell repair and regeneration. This isn't just about selling more pills; it's about owning the telehealth lane for things people are reading about on Reddit and in niche longevity forums. The company is betting on demand for faster recovery and biological upkeep, not just symptom management. It feels like they're trying to outmaneuver the more clinical, higher-barrier longevity clinics by making these treatments more accessible. That puts pressure on traditional clinics to differentiate, and potentially opens up new regulatory questions for the FDA. Keep an eye on pricing and the fine print around who qualifies.